- Home
- FNLC vs DMAC Comparison
FNLC vs DMAC Comparison
Compare FNLC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- DMAC
- Stock Information
- Founded
- FNLC 1864
- DMAC 2000
- Country
- FNLC United States
- DMAC United States
- Employees
- FNLC N/A
- DMAC N/A
- Industry
- FNLC Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- DMAC Health Care
- Exchange
- FNLC Nasdaq
- DMAC Nasdaq
- Market Cap
- FNLC 284.0M
- DMAC 178.0M
- IPO Year
- FNLC 1999
- DMAC N/A
- Fundamental
- Price
- FNLC $27.04
- DMAC $3.76
- Analyst Decision
- FNLC
- DMAC Strong Buy
- Analyst Count
- FNLC 0
- DMAC 2
- Target Price
- FNLC N/A
- DMAC $8.00
- AVG Volume (30 Days)
- FNLC 20.0K
- DMAC 307.4K
- Earning Date
- FNLC 07-23-2025
- DMAC 08-06-2025
- Dividend Yield
- FNLC 5.33%
- DMAC N/A
- EPS Growth
- FNLC 1.61
- DMAC N/A
- EPS
- FNLC 2.52
- DMAC N/A
- Revenue
- FNLC $82,116,000.00
- DMAC N/A
- Revenue This Year
- FNLC N/A
- DMAC N/A
- Revenue Next Year
- FNLC N/A
- DMAC N/A
- P/E Ratio
- FNLC $10.73
- DMAC N/A
- Revenue Growth
- FNLC 5.28
- DMAC N/A
- 52 Week Low
- FNLC $22.11
- DMAC $2.80
- 52 Week High
- FNLC $31.05
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- FNLC 75.28
- DMAC 47.18
- Support Level
- FNLC $25.26
- DMAC $3.48
- Resistance Level
- FNLC $26.51
- DMAC $3.99
- Average True Range (ATR)
- FNLC 0.62
- DMAC 0.32
- MACD
- FNLC 0.30
- DMAC -0.00
- Stochastic Oscillator
- FNLC 98.24
- DMAC 41.01
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.